1. Indications and Usage
\nProphylaxis of Thromboembolic Complications:
\nIndicated for the prevention of thromboembolic complications in patients undergoing surgery (e.g., orthopedic surgery such as hip or knee replacement) or in medical patients at risk of venous thromboembolism (VTE).
\nPrevention of Clotting in Extracorporeal Circulation:
\nIndicated for the prevention of clotting in the extracorporeal circulation during hemodialysis sessions (typically lasting up to 4 hours) in patients without a risk of bleeding.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Subcutaneous Injection ONLY. Must not be administered intramuscularly.
\nRecommended Dosage:
\nSurgical Prophylaxis: The recommended dose is 3,500 anti-Xa IU once daily. The first dose is typically administered 2 hours before surgery or 6 hours after surgery (or later depending on hemostasis).
\nHemodialysis: For patients without bleeding risk:
\nWeight < 60 kg: 2,500 anti-Xa IU administered at the start of dialysis via the arterial line.
\nWeight \u2265 60 kg: 3,500 anti-Xa IU administered at the start of dialysis via the arterial line.
\nAdministration Instructions:
\nInject deeply subcutaneously. It is recommended to alternate injection sites on the abdominal wall (preferably the left or right anterolateral or posterolateral aspects).
\n3. Mechanism of Action
\nLow Molecular Weight Heparin (LMWH):
\nBemiparin is obtained by depolymerization of heparin. It has an average molecular weight of approximately 3,600 Daltons.
\nAnticoagulant Activity:
\nIt acts by binding to Antithrombin III (ATIII), inducing a conformational change that enhances its ability to inhibit Factor Xa. Bemiparin exhibits a high ratio of anti-Factor Xa activity to anti-Factor IIa (anti-thrombin) activity. It primarily exerts its anticoagulant effect through the selective inhibition of Factor Xa.
\n4. Safety and Warnings
\nHeparin-Induced Thrombocytopenia (HIT):
\nContraindicated in patients with a confirmed or suspected history of HIT. Platelet counts should be monitored regularly during treatment.
\nBleeding Risk:
\nAlthough the risk is generally lower than with unfractionated heparin, bleeding can occur. Use with caution in patients with a high risk of bleeding (e.g., active peptic ulcer, hemorrhagic stroke, uncontrolled hypertension).
\nHyperkalemia:
\nLike other heparins, bemiparin can suppress aldosterone synthesis, leading to hyperkalemia, particularly in patients with diabetes, renal failure, or those taking potassium-sparing diuretics. Serum potassium should be monitored if treatment exceeds 7 days.
\nSpinal\/Epidural Hematoma:
\nRisk of spinal or epidural hematoma exists if used concomitantly with neuraxial anesthesia (spinal\/epidural) or spinal puncture.
\n5. Adverse Reactions
\nMost Common:
\nBleeding (e.g., post-operative hemorrhage) and injection site reactions (ecchymosis, hematoma, pain).
\nOther Reported Reactions:
\nThrombocytopenia, elevated liver enzymes (transaminases), hypersensitivity reactions (rash, pruritus), and anemia.
\n6. Drug Interactions
\nAnticoagulants and Antiplatelet Agents:
\nConcomitant use with oral anticoagulants (e.g., warfarin), thrombolytics, or antiplatelet agents (e.g., aspirin, clopidogrel, NSAIDs) may increase the risk of bleeding and is generally not recommended unless strictly supervised.
\nPotassium-Sparing Drugs:
\nConcomitant use with potassium-sparing diuretics or ACE inhibitors may increase the risk of hyperkalemia.
\nDextran 40:
\nConcurrent use is not recommended as it may increase bleeding risk.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Bemiparin Sodium.
\nAvailable Strengths: Prefilled syringes (e.g., 2,500 anti-Xa IU\/0.2 mL and 3,500 anti-Xa IU\/0.2 mL).
\nExcipients: Water for injections, sodium hydroxide, and\/or hydrochloric acid for pH adjustment.
\nStorage:
\nStore below 30\u00b0C. Do not freeze. Protect from light.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u7a00\u4fdd\u00ae(Hibor\u00ae)
\nGeneric Name: Bemiparin Sodium
\nStrength: 3500 IU (anti-Xa)\/0.2mL per pre-filled syringe, 10 syringes per box
\nManufacturer: Rovi Contract Manufacturing, S.L.
\nMarketing Authorization Holder: Laboratorios Farmaceuticos ROVI, S.A.
\nApproval Date in China: 2016
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20160062
\nStorage: Store below 25\u2103, avoid freezing and direct sunlight; keep away from children.<\/p>\n
Price&Cost:Contact Us now for the best price of Bemiparin Sodium \uff08Hibor\uff09<\/p>\n","protected":false},"featured_media":3551,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25],"product_tag":[],"class_list":["post-3550","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n